United-Guardian (UG) investor relations material

Executive summary

• Net sales for Q2 2026 increased 10% year-over-year to $3.1M; six-month sales rose 12% to $6.0M.

• Growth driven by strong recovery in cosmetic and sexual wellness ingredients and pharmaceuticals, offsetting declines in medical lubricants.

• New distribution agreement for Natrajel® and Lubrajel® in North America and France aims to expand market reach.

• Insurance payer outreach led to Renacidin being added to two major PBM formularies in mid-2026.

• Settlement income and gain on sale of asset contributed to net income.

Financial highlights

• Q2 2026 net income was $728,579, up 16% year-over-year; six-month net income reached $1.55M, up 30%.

• Gross margin for Q2 2026 was approximately 49.7%, with cost of sales rising to 50% of sales from 47% in Q2 2025.

• EPS for Q2 2026 was $0.16 (basic/diluted); six-month EPS was $0.34.

• Operating income for Q2 2026 was $754,125; for six months: $1,396,574.

• Investment income decreased 10% for the six months due to lower interest rates.

Outlook and guidance

• Optimism for growth in sexual wellness segment, expected to outpace other categories.

• Renacidin formulary wins and ongoing outreach anticipated to drive future pharmaceutical sales.

• Focus on expanding promotional efforts for Renacidin and increasing market awareness.

• Plans to grow the medical lubricant business and promote “natural” products.

• Working capital and liquidity deemed sufficient for at least the next twelve months.